Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

LifeArc awards £ 1.5 million grant to Vicore Pharma for the VP01 COVID-19 clinical study

Gothenburg, May 29, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that the UK charity LifeArc has awarded the company approximately £ 1.5 million (18.5 MSEK) for the ATTRACT VP01 (C21) COVID-19 study, allowing the company to accelerate the development program by opening more sites.“We are grateful for and pleased with LifeArc’s decision to make a significant financial contribution to our phase II trial with VP01 in COVID-19 patients. Our study was prioritized by an expert panel among a

Pawel Wyszynski new Head of Investor Relations at SEB

Press releaseStockholm 29 May 2020 Pawel Wyszynski has been appointed new Head of Investor Relations at SEB and will assume his position on 7 September 2020. Prior to joining SEB, Pawel Wyszynski has held the position as Director of Shareholder Relations at EQT and he has a solid background as Equity Analyst at Nordea, Danske Bank and Crédit Agricole Cheuvreux.The present Head of Investor Relations, Christoffer Geijer, will join the management team of SEB Investment Management to lead the effort to enhance the distribution of SEB IM’s product offering. For further information,

Omnicar Holding AB Q1 2020 report

Q1 (2020-01-01 - 2020-03-31) · Total revenue and other income SEK 3374 thousand · Q1 profit after financial income and expenses, net amounted to SEK 269 thousand · Q1 earnings per share* is SEK 0,02 for the quarterDear shareholder, Today, we are releasing our Q1 2020 report together with our audited numbers for 2019. Our turnaround is now complete, and we have a solid starting point for 2020. We can show profit figures and our customer base is loyal and happy. As a company,we are not severely hit by COVID-19, mainly because we have made a huge effort to become a lean

Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

GOTHENBURG, Sweden, May 29, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”), has been informed by Professor Bengt Gustavsson – founder and largest owner of Isofol – that Professor Gustavsson has initiated that all the subscription rights held by Biofol AB (an affiliated company to Professor Gustavsson), obtained in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million, has been purchased by a consortium of investors.The consortium of investors has committed to Professor Gustavsson that

NEW NUMBER OF SHARES AND VOTES IN SOTKAMO SILVER

Press release, May 29, 2020, Stockholm, 08:45 CESTAs previously announced, Sotkamo Silver AB (“Sotkamo Silver”) has completed a rights issue of 44,994,433 shares. As a result of the rights issue, the number of shares and votes in Sotkamo Silver has increased during the month of May. Prior to the rights issue, the number of shares and votes in Sotkamo Silver amounted to 134, 983,299. 44,994,433 new shares have been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) during May. Hence, as of today, May 29, 2020, the last trading day of the month, the number of

Zlatko Rihter appointed new CEO of Mölnlycke

Zlatko Rihter has been appointed President and CEO of the medical solutions company, Mölnlycke Health Care AB.Zlatko Rihter is a Swedish citizen and currently President and CEO of Sweden-based CellaVision, a world-leading provider of digital solutions for medical microscopy in the field of hematology, listed on Nasdaq Nordic. “We are very pleased to see Zlatko Rihter joining Mölnlycke. He brings solid knowledge from the medtech industry and a strong track record of growth based on innovation and customer focus,” says Gunnar Brock, Chairman of Mölnlycke. Zlatko Rither has extensive

2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal

2cureX AB (“2cureX”, NASDAQ: 2CUREX) today announces that the company has established a new partnership agreement to support the commercialization of IndiTreat in Portugal and Spain. The partnership agreement will support the company’s efforts to increase commercial activities and interactions with public and private hospitals in these markets. 2cureX is in the process of launching the IndiTreat® test in the European market.The distribution partnership will help position IndiTreat towards a larger customer base and will utilize the knowledge of our distribution partner in the Oncology

Temporary change in number of shares and votes in Tethys Oil

Tethys Oil has, in accordance with previously announced resolution on the Annual General Meeting (“AGM”) on 13 May 2020, launched a mandatory share redemption procedure whereby every share in Tethys Oil is split into one ordinary share and one redemption share. As a result, the number of shares and votes in Tethys Oil has changed. The change is temporary since the same AGM also resolved on a redemption of the new shares.As per 29 May 2020, the total number of shares amounts to 72,589,920, of which 36,294,960 are ordinary shares and 36,294,960 are redemption shares. The total number of votes

Change in number of shares and votes in NOTE

The total number of shares and votes in NOTE has changed consequent upon the issue of 500,000 new shares in May upon exercise of warrants in the incentive programme adopted by the Annual General Meeting held on 20 April 2017.Subsequent to the exercise of warrants, the total number of shares and votes in NOTE at 29 May 2020 was 28,372,600. Through the exercise of warrants, NOTE’s share capital has increased with SEK 258,969.39 and, as of 29 May 2020, amounted to SEK 14,695,269.39.For more information, please contact:Johannes Lind-Widestam, CEO and President, tel. +46 (0)70 541 7222

Fire in crushing station at Boliden Kevitsa

During last night a fire occurred in the building for primary crushing in Boliden´s mine Kevitsa, located in Finnish Lappland. No person were injured and the extinguishing work are now completed. The damages are extensive and investigations are initiated with the aim of assessing which actions are necessary to resume operations. As a result, production at the concentrating plant are halted until further notice, mining production is unaffected.   For further information, please contact:Klas Nilsson, Director Group Communications, phone: +46 70 453 65 88  Boliden is a metals

Fazer Cafés to reopen on 1 June

Fazer Cafés are set to reopen their doors on 1 June. The cafés have been closed due to the coronavirus pandemic since late March. A new café, Fazer Café Kamppi, is also opening on the following day. Special attention has been paid to the safety of both customers and staff.On Monday 1 June, Fazer is reopening its Fazer Cafés which have been closed since 28 March in accordance with the proposition of the Finnish government. During the exceptional spring, all Fazer Cafés, including the iconic Fazer Café Kluuvikatu, have been closed, except for the cafés in Munkkivuori and Töölö, which were

Change in number of shares and votes in AddLife AB

The total number of shares and votes in AddLife AB, reg. no 556995-8126, (“AddLife”) has changed in May 2020 consequent upon that the number of A-shares have increased with 3,468,912 A-shares and the number of B-shares have increased with 82,404,807 B-shares upon the Annual General Meeting in AddLife held on 7 May 2020 resolving on a share split (4:1). After the share split the total number of shares as per 29 May 2020 amounts to 114,498,292 of which 4,625,216 A-shares and 109,873,076 B-shares, corresponding to in total 156,125,236 votes. AddLife’s share capital of SEK 58,309,339.55

Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer

28 May 2020 22:00 BST Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer Phase III ADAURA trial showed treatment with Tagrisso after surgery withcurative intent reduced the risk of disease recurrence or death by c. 80% Detailed results from the Phase III ADAURA trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA)

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In May, at the request of shareholders 199,046 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,275,187,629.The total number of registered shares in the company amounts to 702,342,489 of which 63,649,460 are Class A shares

Interim report for the period 1 January – 31 March 2020

First quarter of 2020 Numbers in parentheses refers to outcomes during the corresponding period of the previous year. · Revenues of SEK 0 million (0). · Operating costs increased to SEK 1.0 million (0.5) due to work with the Jaffa port expansion. Administrative expenses increased to SEK 3.3 million (0.9). The increase is largely explained by that the Company was not listed and had no office in Stockholm in Q1 2019 and that new hires have been made in Israel in the end of 2019. · Profit (loss) for the period amounted to SEK -4.4 million (-1.7). · Earnings per share of SEK -0.

New number of shares and votes in Haldex

The total number of shares and votes in Haldex Aktiebolag (publ) has during May changed due to that 4,421,597 new shares have been issued to AMF Pensionsförsäkring and AFA Försäkring trough a directed new shares issue. More information about the directed new share issue can be found in the press release from 10 May 2020. As of 29 May 2020, the total number of shares and votes in Haldex amounts to 48,637,567 and the share capital amounts to SEK 243,187,835.   For further information, please contact: Helene Svahn, CEO Phone: +46 418 47 60 00 E-mail: katarina.ronne@haldex.com

Interim Report January - March 2020

JANUARY–MARCH 2020 (COMPARED WITH JANUARY–MARCH 2019) · Total credit portfolio[1] increased by 47 % to SEK 1 598 million (1 083) · Net interest income increased by 29 % to SEK 87.5 million (67.9 · Operating income increased by 27 % to SEK 99.7 million (78.3) · Profit before tax (EBT) decreased by 76 % to SEK 5.7 million (23.9) and Adjusted EBT[2] decreased by 12 % to SEK 21.0 million · Cost/income ratio totaled 0.34 (0.30) · Return on equity was 22.2 % (31.8 %) · Total capital ratio was 22.0 % in Northmill Bank AB and 19.8 % in the Group · Common Equity Tier 1

New number of shares and votes in Moberg Pharma AB (publ)

STOCKHOLM, May 29[th], 2020, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 19,223,510. The 370,000 newly issued shares are held by the company to secure its commitments under incentive programmes.As per 29 May 2020, the total number of shares in Moberg Pharma AB (publ) amounts to 19,223,510. All shares are common shares. The total number of votes are 19,223,510. The increase in the number of shares and votes results from an issue of 370,000 class C shares. The newly issued class C shares have been repurchased and, by virtue of

Increased number of shares and votes in Bactiguard

During May 2020, the number of class B shares in Bactiguard Holding AB (publ) ("Bactiguard") has increased by 241,512. As a result, the total number of shares in the company as of May 29, 2020 amounted to 29,543,885 and the total number of votes to 69,543,885.The increase is a result of the new issue of shares by way of set-off that was approved by the Annual General Meeting on April 28, as part of the payment for Vigilenz, as earlier communicated. The total number of shares in Bactiguard has increased by 241,512 class B shares and as of the last trading day in May (29 May 2020) amounts

Hansa Biopharma appoints Achim Kaufhold as CMO to support the expansion outside transplantation

Hansa Biopharma appoints Professor Achim Kaufhold, M.D., a highly experienced senior leader in immunology, infectious diseases and oncology, as Chief Medical Officer. Achim Kaufhold joins the company on June 1st and will be a Member of the Executive Committee. He will support the Company´s expansion outside transplantation and report to Søren Tulstrup, President and CEO.Lund May 29, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company has appointed  Professor Achim Kaufhold, a very seasoned senior

Interim report January - March 2020

Quant releases the interim report for January - March 2020.January-March · Net sales for the period decreased by 11.6% to EUR 43.6 (49.3) million. Organically, net sales decreased by 9.6% · During the quarter, the contract portfolio developed negatively. Four contracts were renewed, no contract was won and seven contracts were lost or exited. Portfolio run rate annualized net sales at the end of the quarter was EUR 175.1 million, compared to EUR 187.0 million during the fourth quarter of 2019 · Operating loss amounted to EUR -1.7 million, compared to a loss of EUR -1.4 million

Christina Kassberg appointed CFO of Climeon

Climeon has appointed Christina Kassberg Chief Financial Officer (CFO). Christina Kassberg has long and solid experience as CFO and in financial management. She will assume her new role on June 8, 2020. - We are incredibly proud to have succeeded in recruiting Christina Kassberg to Climeon. Christina's business focus and broad experience as CFO of both small and large listed companies, companies in a growth phase as well as more mature companies is an incredible strength in the phase Climeon is in, says Thomas Öström, CEO of Climeon. - Based on past experience and with a strong

Change in the total number of shares and votes in Recipharm AB (publ)

As of 29 May 2020, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 72,300,679 shares, divided into 15,222,858 shares of series A and 57,077,821 shares of series B. The total number of votes in Recipharm as of 29 May 2020 amounts to 209,306,401. The number of shares and votes in Recipharm has increased as a result of the directed share issue of 4,524,886 shares of series B raising approximately SEK 500 million to Recipharm before issue costs.  For more information please visit www.recipharm.com or contact:Thomas Eldered, CEO, ir@recipharm.com, telephone:

There are no items matching the current filter
There are no more items matching the current filter
Back to top